Andrx loratadine/pseudoephedrine
Executive Summary
FDA accepts ANDA for a potential bioequivalent version of Schering's Claritin D-24. The Orange Book lists three patents covering immediate-release loratadine expiring in 2002, 2004 and 2008, and an additional patent that expires in 2012
FDA accepts ANDA for a potential bioequivalent version of Schering's Claritin D-24. The Orange Book lists three patents covering immediate-release loratadine expiring in 2002, 2004 and 2008, and an additional patent that expires in 2012. |